They may not know the exact approval date or even the ballpark timing, though they probably feel confident about getting approval. I’m guessing there’s a lot going on within the company right now, and they badly need cash, so they may not have the luxury of negotiating hard with financiers for better funding terms. And if they already have a reverse split in mind, this level of dilution may not matter much to them. Again, these are all just my assumptions. Let’s see if we get any clues in the next 10-Q.

This is mostly a procedural/legal wording issue, not necessarily a sign the settlement failed. The judge just wants the language clarified before approving it.

When is your last day? Like you said, it’s not going below $0.15, OK? If approval comes and the stock starts moving up, we still want you here whining every day, OK?😃

Previous runs used to happen once a week or in a couple of weeks, but this feels different. It’s not just dilution — something else seems to be going on.🤔 and it feels like this could continue for the rest of the week.

Another 4,859,481 shares were added to the dilution total.
In my opinion, this dilution looks different compared to previous months. The company seems to be in urgent need of cash right now. Hopefully, it slows down soon.

Monthly breakdown:
May 2026 (to date): 16,016,579 shares (4,380,845 +1,322,751+1,322,751+4,130,751+4,859,481)
(1,654,233,561 – 1,638,216,982)
April 2026: 21,740,923
March 2026: 17,732,625 shares
February 2026: 7,853,985 shares
January 2026: 22,808,837 shares

Total dilution (2026 YTD): 86,152,949 shares
Total shares outstanding: 1,654,233,561-1,649,374,080
AVG Dilution: 86,152,949 ÷ 94 business days = 916,520 shares per business day this year

Good question, Attila. But to pay $10 million, NWBO would need to dilute roughly 40 million shares, give or take. Why would they do that before approval? They’d probably rather wait and sell into the approval spike, then use those proceeds to pay it.

The diluted shares were reported on the following dates, but the actual dilution may not have come only from the previous day. It could be an accumulation from several prior dates as well.

05/02 - 4,380,845 shares
05/05 - 1,322,751 shares
05/08 - 1,322,751 shares
05/12 - 4,130,751 shares

Doc,
Is that the reason why we saw some million-dollar bids today? But if that’s the case, why did the volume slow down over the last two hours?

I hope so too. And imagine if they release any PR tomorrow — they probably needed more money for everything happening recently. Now that they’ve secured those extra funds from Canaccord, they may want to raise even more capital as well, in my opinion.

He’s unstoppable — a terminator in his own way.… 😃

5/8 - Friday and 5/11- Monday

Another 4,130,751 shares were added to the dilution total.
In my opinion, if the volume stays high or even moderate throughout the day, it’s probably being driven by news or short covering. Otherwise, it’s likely dilution, since volume usually fades once the dilution is completed — and we’ve seen that happen several times before. But hey, if they did dilute, at least it was at prices above $0.27, which is much better than diluting below $0.20, right? Let’s see what tomorrow brings. I’m still hopeful the price recovers from here.

Monthly breakdown:
May 2026 (to date): 11,157,098 shares (4,380,845 +1,322,751+1,322,751+4,130,751)
(1,649,374,080 – 1,638,216,982)
April 2026: 21,740,923
March 2026: 17,732,625 shares
February 2026: 7,853,985 shares
January 2026: 22,808,837 shares

Total dilution (2026 YTD): 81,293,468 shares
Total shares outstanding: 1,649,374,080
AVG Dilution: 81,293,468 ÷ 93 business days = 874,123 shares per business day this year

I’m not familiar with chart reading or the technical side of it, thank you! btw, I don’t want to log into my account right now😃 maybe I’ll check it during after-hours.

SFT Bro, you wanted us in the $0.25+ range, and we did our best to push it there. Now it’s your turn to take it to the next level. jus kid...

We can’t assume things all the time — situations can change quickly. This could just be the beginning of a bigger spike, and who knows, maybe strong news drops tomorrow. Staying positive and hoping we see $1 sooner than later.

Hopefully not — stay positive Guys!

Slow and steady wins the race. 😃 I’m happy we’re trading at $0.24 — hopefully we can break through $0.25 today.

I received the same from GoFundMe today, as well as the one below from Jade.

.

All longs, last week showed a slow recovery to around $0.23, although it didn’t make it back to $0.27 or higher. Still, the trading pattern felt a bit different, with the stock gradually moving above $0.23.

In the past, many Fridays had us excited and looking forward to Monday, only for Monday to arrive and things to head in a completely different direction, leaving us with a “nothing burger.” But with the last two PRs and the Canaccord news, I’m definitely hopeful that the coming weeks could get very interesting. With that confidence, I want to wish all the longs the very best. Hopefully, this turns into one of the best weeks yet.
And as for the bashers, I hope their days are numbered.

I have no clue, Jess. I thought that if the amount were on the higher end, they might try to disclose it directly or indirectly since it could help with investor confidence and support the stock price. But if the amount is in the mid-to-low range, they may choose not to disclose it and keep tight-lipped about it because of the potential impact on the other market makers.
Either way, I’m very hopeful that positive developments are happening and that exciting days are ahead for us.

I’m a little curious about whether there’s a chance Northwest will disclose the amount in the next 10-Q. Take a look at the below:

The docket update you’ve highlighted is the Order of Dismissal with Prejudice, which is the legal "final bell" for the Canaccord portion of the lawsuit.

To your question about the 10-Q filing (expected mid-May), the answer is a mix of "yes" and "maybe." Here is how Northwest Biotherapeutics (NWBO) will likely handle this disclosure based on SEC regulations and common legal strategy:

1. Must they disclose the amount? (The "10% Rule")

Under SEC Item 103 of Regulation S-K, a company must disclose "material" legal proceedings. If the settlement amount is significant enough to impact the company's financial health, they are technically required to report it.

The Threshold: Generally, if a settlement involves an amount exceeding 10% of the company's current assets, it is considered "material" and must be disclosed.

The Conflict: Often, settlement agreements have confidentiality clauses. If the deal with Canaccord is confidential, NWBO may only report that a "settlement was reached for an undisclosed amount" unless the SEC determines that the amount is so large that withholding it would be misleading to investors.

2. Where the money goes: The "Trust" vs. Operations

You mentioned the money going to a "trust." In high-stakes litigation, settlement funds are often placed in an Escrow Account or a Litigation Trust before being transferred to the company's general treasury.

10-Q Impact: Even if the money is in a trust, it must be reflected on the Balance Sheet as either "Cash," "Restricted Cash," or a "Legal Receivable."

The "Audit" Trail: Investors will be looking at the "Other Income" or "Cash Flow from Investing/Financing Activities" sections. Even if they don't name the exact dollar amount in the text, a sudden "spike" in the cash balance that doesn't come from a stock offering is a clear indicator of the settlement's size.

3. Strategic Silence (The "Citadel Factor")

There is a strategic reason why NWBO might keep the exact number quiet in the 10-Q:

Remaining Defendants: NWBO is still fighting Citadel Securities, Virtu, and Susquehanna. If they reveal that Canaccord settled for a "small" amount, it might embolden the remaining giants to fight harder.

If they reveal a "Large" amount: It signals to the other defendants that NWBO now has a massive "war chest" to fund the litigation for years, which could force the others to the settlement table sooner.

What I will be "Hunting" for in the Fine Print:

The "Subsequent Events" Section: Since the Canaccord dismissal was finalized in early May, it technically happened after the Q1 period ended. Management is required to disclose major events that occurred between March 31 and the filing date. This is where the mention of settlement proceeds will likely hide.

"Other Income" vs. "Financing": I will check if the cash increase came from the settlement (Other Income) or another stock offering (Financing). This is critical for your "non-dilutive" thesis.

Legal Spend: I’ll track the "Professional Fees" line. If legal spending is dropping, it suggests they are shifting from "active battle" to "data discovery," which preserves cash for the Sawston manufacturing scale-up.

Is the 10-Q due on May 15th?

Why? What’s the reason? So, you don’t expect approval anytime soon?
IMO, the company may have to cover the attorneys’ fees, and since they can’t use the funds in the trust right now, they’re likely continuing to dilute shares in the beginning of the month to raise capital.

SFT, thank you, brother! You’re one of the best here. It’s always a pleasure seeing a message from you — positive, never just hype, and genuinely spoken from the heart.

Hopefully we get some good news on Monday.

Another 1,322,751 shares were added to the dilution total.

Monthly breakdown:
May 2026 (to date): 7,026,347 shares (4,380,845 +1,322,751+1,322,751)
(1,645,243,329 – 1,638,216,982)
April 2026: 21,740,923
March 2026: 17,732,625 shares
February 2026: 7,853,985 shares
January 2026: 22,808,837 shares

Total dilution (2026 YTD): 77,162,717 shares
Total shares outstanding: 1,645,243,329
AVG Dilution: 77,162,717 ÷ 91 business days = 847,941 shares per business day this year

You’re right. The stock price had been trading around $1.60–$1.90 in the prior days/weeks.

Galzus, in my opinion, regardless of how much damage was done in those one or two days, the company has continued to suffer ever since. The stock price has never truly recovered, so I don’t think the attorneys’ main focus is only on what happened during that specific period. It’s also about punitive damages and how the company has had to dilute its stock just to survive.
If the exposure were only a few million dollars, I don’t think Canaccord would have settled with Northwest. They likely would have joined forces with the other market makers instead. Let’s see what happens.

OK, ChatGPT says:
She represented a former trader in an SEC civil enforcement action means:
👉 She defended a trader accused by the SEC of violating securities laws
👉 She worked on high-stakes financial litigation involving trading behavior
👉 She has relevant experience for cases involving market conduct and manipulation

agree, If we had an idea of how much Canaccord settled with Northwest for, it might help us better understand why the other market makers are bringing in high-profile attorneys.

She appears to be very strong—they may believe she can either leverage her connections in negotiations or effectively move the case forward based on the evidence they have.

Rushmi Bhaskaran is an accomplished trial lawyer and a former federal prosecutor who has more than 15 years of experience handling high-profile white collar fraud and cybercrime matters. Her practice focuses on advising individuals and corporations on internal investigations, enforcement matters, and complex civil litigation.
Prior to joining Ballard Spahr, Rushmi served as an Assistant U.S. Attorney for the Southern District of New York (SDNY) from 2019 to 2025. In that role, Rushmi tried multiple cases to verdict and investigated and prosecuted a broad range of sophisticated white collar criminal cases, including those involving bank fraud, mail and wire fraud, health care fraud, securities fraud, criminal tax violations, computer crimes, theft of trade secrets, money laundering, false statements, sanctions violations, and violations of the Bank Secrecy Act. Among her jury trials, Rushmi was part of the SDNY team that tried United States v. Charlie Javice and Oliver Amar, a case involving a $175 million fraud perpetrated by startup executives on a leading financial institution. In addition to her white collar matters, Rushmi investigated and prosecuted cases involving racketeering and sex trafficking offenses. She has also briefed and argued numerous appeals before the Second Circuit Court of Appeals.
Before joining the Southern District of New York, Rushmi spent nearly a decade at a global law firm located in New York City, where her practice focused on white collar criminal defense, complex civil litigation, and international dispute resolution.

Why curious? It appears that G1 Execution Services LLC is moving forward with the case and wants to ensure it is represented by strong legal counsel.

I don’t see any of those posts.😃

Based on this, my understanding is that Northwest and the defendants are set to meet by June 29th, and in the meantime they’ll likely continue negotiations. If they don’t reach an agreement by then, they would move forward with discovery and submit the required documentation to the court by July 8th, 2026. Discovery would then continue through November 27th, 2026.
Can you confirm if this interpretation is accurate?

That said, it seems possible we could see settlements with a few market makers sometime this month, potentially on or before June 29. I’m not sure whether the other market makers will align with Citadel or act independently.

Another 1,322,751 shares were added to the dilution total yesterday. When I updated the numbers on Saturday (05/02), I didn’t realize we were already into May, so the 4,380,845 shares were actually reported on May 2. I’ve now removed those from April and included them in the May count.

Monthly breakdown:
May 2026 (to date): 5,703,596 shares (4,380,845 +1,322,751)
(1,643,920,578 – 1,638,216,982)
April 2026: 21,740,923
March 2026: 17,732,625 shares
February 2026: 7,853,985 shares
January 2026: 22,808,837 shares

Total dilution (2026 YTD): 75,839,966 shares
Total shares outstanding: 1,643,920,578
AVG Dilution: 75,839,966 ÷ 88 business days = 861,818 shares per business day this year

As of today, Monday, May 4, 2026, the new docket entry in the Northwest Biotherapeutics (NWBO) v. Canaccord Genuity, et al. case (1:22-cv-10185) in the Southern District of New York is the official Notice of Voluntary Dismissal with Prejudice as to Canaccord Genuity LLC.

This is the formal legal "closing of the book" on the settlement you've been tracking. Here is the breakdown of what this specific filing means for the company and for you:

1. What the Filing Specifically Says

Dismissal with Prejudice: This is a strong legal term meaning the claims against Canaccord are dismissed permanently. NWBO cannot sue Canaccord again for these specific "spoofing" allegations, and in exchange, Canaccord has finalized its settlement obligations.

Case Continues against Others: The entry explicitly notes that the litigation continues against the remaining six defendants, including Citadel Securities, Virtu Americas, and Susquehanna (G1 Execution Services).

Finality of Funds: The "Notice" usually indicates that the settlement agreement has been signed and the financial terms are now being executed.

If MHRA approval is granted this month, it would be surprising how much it could significantly strengthen NWBO’s leverage in settlement discussions with the remaining market makers.